Reference
Gross ME, et al. Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for castration resistant prostate cancer (CRPC). Journal of Clinical Oncology 33: No. 151, 20 May 2015 [Abstract] - USA
Rights and permissions
About this article
Cite this article
Bevacizumab/docetaxel/everolimus. Reactions Weekly 1572, 41 (2015). https://doi.org/10.1007/s40278-015-1066-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-015-1066-z